Pooled analyses of the roxadustat global Phase III programme confirmed cardiovascular safety
Cardiovascular safety endpoints evaluated across CKD patients not on dialysis, on incident dialysis and on stable dialysis Better outcome vs. epoetin alfa in incident-dialysis patients and comparable to placebo in patients not on dialysisAstraZeneca today announced top-line results from the pooled cardiovascular (CV) safety analyses of the global Phase III programme for roxadustat, a first-in-class hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI). The global pivotal Phase III trials evaluated roxadustat for treatment of anaemia in patients with chronic kidney disease (CKD)